no specific action is usually taken to revert the clinical deficit and hence prevent poor outcomes. However, although hemodynamic and metabolic factors are suspected as underlying mechanisms, 9 this has not been directly examined to date. To date, unexplained END has been only addressed in nonthrombolysed AIS, 10 which may not generalize to the IV-rtPA setting. Thus, the incidence, predictors, and associated factors of postthrombolysis END unexplained are still largely unknown and are the topic of the present work.
Methods

Patients
We extracted all consecutive patients who received IV-rtPA within 4.5 hours of stroke onset between January 2003 and March 2013 from our prospective database, increased to 4.5 hours from 2008. Patients who underwent endovascular therapy were excluded given that in this setting the END may be directly related to the procedure. We then selected patients with middle cerebral artery (MCA) stroke because it is the most common subtype and its pathophysiology is well known. Decision to treat by IV-rtPA was made by stroke neurologists according to current European guidelines, except that age >80 years was not a contraindication. Relevant clinical data were extracted from the database (see online-only Data Supplement). Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) before and at 1 and 24 hours after treatment. Poor outcome was defined as 3-month modified Rankin Scale score >2.
In accordance with French legislation, Institutional or Ethics Committee approval was not required for this study because it only implied retrospective analysis of anonymized data collected as part of routine clinical care. Likewise, written consent was not necessary for IV-tPA, which is part of routine care.
Imaging Protocol
MRI is systematically implemented as first-line pretreatment workup in candidates for thrombolysis in our center. 11 The admission protocol, performed on a 1.5-T scanner (Signa EchoSpeed, GE Healthcare), included fluid-attenuated inversion recovery, diffusion-weighted imaging (DWI), T2*-weighted gradient echo imaging, intracranial 3-dimensional time-of-flight magnetic resonance angiography, and perfusion-weighted imaging (PWI) whenever feasible. The DWI-PWI patterns and hypoperfusion or DWI lesion volumes were not the basis for clinical decision making except when there was uncertainty of potential for benefit. Patients in whom MRI was contraindicated underwent computed tomography (CT) and, whenever feasible, CT angiography; CT perfusion was performed only occasionally. A follow-up imaging (MRI, or CT if contraindicated) was scheduled ≈24 hours after treatment and included the same set of sequences as the admission MRI save for PWI. Additional magnetic resonance or CT was also obtained in case of early worsening. The following admission magnetic resonance variables were considered for the statistical analysis: DWI volume, hypoperfusion volume (T max >6 s), 11 DWI-PWI mismatch volume (ie, the volume of hypoperfusion without DWI lesion on coregistered images), and presence of proximal (internal carotid artery or M1 MCA) arterial occlusion. Recanalization was defined as a thrombolysis in cerebral infarction score ≥2 on follow-up magnetic resonance angiography.
12
Unexplained END
END was defined as an NIHSS score increase (∆NIHSS) of ≥4 points between baseline and 24 hours, as used in previous studies on posttPA END. [3] [4] [5] The first 24 hours is the critical period for both favorable and unfavorable evolution, 1 the special case of malignant edema apart. 13 The medical and radiological records of each END case were reviewed by a stroke physician (P.S.) and a neuroradiologist (M.T.) and adjudicated in consensus for potential cause, taking into account the sudden or progressive onset of the deterioration, the neurological function that worsened, and the findings on imaging performed at the time of deterioration. sICH was identified according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria, defined as parenchymal hemorrhage type 2 based on European Cooperative Acute Stroke Study (ECASS) imaging classification on the imaging obtained at time of worsening and a ∆NIHSS ≥4 deterioration.
14 Early malignant edema was considered if brain swelling and midline shift were present together with worsening of consciousness. Early recurrent ischemic stroke was defined as the occurrence of new neurological symptoms suggesting the involvement of initially unaffected vascular territories and evidence of corresponding ischemic lesions on follow-up imaging, which excludes arterial reocclusion, proximal extension, or distal embolism of the original thrombus. 15, 16 Thus, END unexplained was operationally defined as END without evidence for any of the above causes or other potentially causative definite medical complication (eg, poststroke seizure).
Statistical Analysis
Continuous variables with a normal distribution were described as mean±SD and non-normally distributed variables as median and interquartile range. END patients with a cause were excluded from further analysis. Associations between END unexplained and pre-or posttreatment variables were assessed as odds ratios (ORs) and 95% confidence intervals (95% CIs) in univariate logistic models with END unexplained as the dependent variable. Pre-and post-treatment variables associated with END unexplained in univariate analysis at a level of P<0.20 were candidates for inclusion into a multivariate logistic model. However, ≈1 predictor can be entered into a multivariate logistic regression model for 10 events of the dependent variable. 17 Therefore, considering the relatively small number of END unexplained in this sample (see Results), we used oblique principal component cluster analysis for variable reduction. Exploratory multivariate logistic regression was then used with the remaining variables, using a Firth correction, which is less prone to overfitting. We then performed an internal validation of each final logistic model (pre-and post-treatment models), based on 1000 bootstrap replicates. Statistical analyses were performed using SAS 9.3 (SAS Institute, Inc, Cary, NC) and SPSS 16.0 (SPSS Inc).
Results
Study Population
During the study period, 119 consecutive patients (81 with MCA stroke) underwent endovascular procedures and were excluded a priori, and 353 patients only received IV-rtPA. Of these, 44 were excluded for the following reasons: non-MCA stroke (n=36), lacunar stroke (n=4), and miscellaneous (n=4), leaving 309 patients for the present analysis, of which 279 had admission MRI and 30 had CT. The baseline characteristics of the studied population are shown in Table 1 . The median (interquartile range) baseline NIHSS score was 15 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , and the mean age was 69±15 years. Occlusion involved the internal carotid artery in 80 patients, including 9 (3%) with isolated internal carotid artery occlusion and 71 with tandem internal carotid artery-MCA occlusion, M1 in 176 (57%) and M2 in 83 (27%), and no occlusion in 35 (11%). The initial arterial status could not be assessed in 6 (2%) patients.
END occurred in 33 (11%) patients. Identified causes were sICH in 6 (2%) and early swelling in 4 (1%), leaving 23 (7%) patients with END unexplained . Parenchymal hematoma type 1 was present on follow-up MRI in 1 END unexplained patient but was judged unrelated to the severe END (13 NIHSS points). No patient deteriorated because of early recurrent ischemic
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stroke. Timing of END unexplained after tPA was within 2, 2 to 6, 6 to 12, and 12 to 24 hours in 5, 5, 5, and 8 patients, respectively. Among END unexplained patients, 2 had a significant initial improvement (≥4 NIHSS points at 1 hour) followed by neurological deterioration.
Pretreatment Variables Associated With END unexplained in Univariate Analysis
The pretreatment characteristics of patients with and without END unexplained and the results of the univariate analyses are presented in 
Factors Associated With Unexplained END During the First 24 Hours
Clinical and radiological data during the first 24 hours posttreatment are shown in Table 2 . There was a trend for significance for median glycemia level during the first day, higher in deteriorating patients (P=0.06), whereas there was no association with maximum glycemic change. No patients had episodes of hypoglycemia (<4 mmol/L). Mean systolic blood pressure within the first 24 hours was marginally higher in END unexplained patients (P=0.045), but maximum blood pressure change was not different between the 2 groups. On post-treatment imaging, END unexplained patients had a significantly higher rate of no recanalization (P<0.01). Final exploratory multivariate model including median glycemia, mean systolic blood pressure, and recanalization showed that only no recanalization (adjusted OR=4.18; 95% CI, 1.28-13.69; P=0.02) was associated with END unexplained (c-statistic of the model=0.72). These results were confirmed by internal validation using the bootstrap approach (online-only Data Supplement).
Outcome
END unexplained was associated with poor 3-month outcome as compared with non-END patients in univariate analysis (P<0.01; Table 2 ).
Discussion
This study is the first to assess specifically the incidence of unexplained END within 24 hours after IV-rtPA for AIS. The observed incidence of 7% is sizeable and hence clinically relevant. We also report the first clinical and radiological predictors of 24-hour unexplained END after IV-rtPA, showing a strong protective effect of prior antiplatelet therapy as well as an association with lower admission NIHSS, higher blood glucose and mismatch volume, presence of proximal arterial occlusion, and lack of recanalization. The incidence of 11% for all-cause END in our study is consistent with 3 recently published series of IV-rtPA-treated patients (reported range, 10%-16%) that used the same END definition. [3] [4] [5] Only 2% had sICH, similar to a recent report also using the SITS-MOST definition.
14 No patient worsened because of early recurrent ischemic stroke, consistent with its previously reported low incidence. 15, 16 Importantly, unexplained END represented 7% of all IV-rtPA-treated patients with AIS and more than two thirds of all-cause ENDs. Thus, the majority of ENDs have no clear underlying mechanism. Although no previous study of unexplained END after IV-rtPA is available for comparison, an incidence of 10% unexplained END has been reported in nonthrombolysed mild strokes. 10 Finally, consistent with the available literature, [2] [3] [4] we found unexplained END to be associated with poor outcome. Overall, therefore, most deteriorations occurring within 24 hours post-thrombolysis are unexplained yet predict poor outcome, underlying the need to understand their underlying mechanisms to prevent or treat them. Identifying predictors of this ominous complication was our next objective. Our choice of potential predictors of END unexplained over and above standard variables such as age and admission NIHSS was guided by its putative mechanisms, notably worsening of perfusion or neuronal function beyond the penumbra attributable to, for example, blood pressure drops or swings, hyperglycemia, and thrombus extension in the context of persistent arterial occlusion. 9 Lending support to this mechanism, 3 [18] [19] [20] shown in one to impact clinical course negatively. 18 However, whether END was associated with these observations was not reported. Our findings strongly suggest that prior use of antiplatelet treatment may afford protection against END unexplained . One previous study reported a similar finding but included sICH, 3 which in fact strengthens the idea that prior antiplatelet use protects against unexplained END. Our finding is also consistent with another study assessing 3-month outcome. 21 Thus, antiplatelets may protect against thrombus extension and same-territory recurrent embolization, 22 as well as against reocclusions. 5 Consistent with studies on all-cause END after thrombolysis, 4, 23 higher admission glycemia was the second strongest predictor of unexplained END. This association could be accounted for by increased brain lactate production precipitating severely hypoperfused tissue into infarction 24 and disrupting cell metabolism within mildly hypoperfused tissue, causing it to become symptomatic. Of note, however, a recent trial found that insulin therapy did not influence infarct growth despite significantly attenuating brain lactate increases. 25 Interestingly, hyperglycemia also has prothrombotic effects, hindering recanalization after IV-rtPA 26 and perhaps also facilitating thrombus extension.
A third robust predictor of END unexplained was lower admission NIHSS score, again consistent with 1 previous report. 4 This association might not only represent the ceiling effect intrinsic to this scale, preventing high scores from further escalating, but also reflect the increasingly reported risk of early deterioration in minor strokes, especially when associated with proximal occlusion. 10, 27 Finally, consistent with 2 previous reports, 2,4 proximal occlusion was predictive of END unexplained , as was also larger mismatch. Both factors may actually be related in that proximal occlusion entails larger hypoperfused volumes, 28 in turn exposing to the risk of secondary worsening. In contrast, in the only previous study that directly assessed this relationship, END was associated with smaller DWI-PWI mismatch. 29 However, in this study, END was assessed at 48 hours, and in 5 of the 7 index patients, it was clearly related to malignant edema, entailing a large core and hence smaller mismatch. 29 The relationship between mismatch volume and END may therefore change over time, further emphasizing the need to consider END within the first 24 hours as a separate clinical entity.
Associated Factors During the First 24 Hours
Lack of recanalization at 24 hours was strongly associated with END unexplained , consistent with 1 study of all-cause END 30 and further strengthening the already discussed critical role of intracranial hemodynamics. There was also a strong trend for an association with higher glycemia during the first day, perhaps via the mechanisms discussed above. Although glycemic swings and episodes of (iatrogenic) hypoglycemia may also contribute to neuronal death, the former was not found to be associated with END unexplained , while the latter never occurred.
Taking together all the above findings, our study suggests that, in a background of persistent occlusion and extensive mismatch, disruptions in local perfusion pressure secondary to thrombus extension or distal embolization together with high blood glucose at onset of ischemia play an important role in END unexplained after IV-rtPA. Early endovascular therapy, which allows higher rates of recanalization, may therefore be an attractive option for patients at high risk of, or experiencing, END unexplained .
Our study has limitations. First, we elected a change of ≥4 NIHSS points to define END because smaller changes could be affected by limited reliability, especially for high scores. 31 Although widely used, this cutoff is somewhat deliberate and its functional significance may differ with stroke severity. To address this, we performed a post hoc sensitivity analysis using a relative change of ∆NIHSS ≥30% as alternative cutoff, whereby END reflects a larger absolute increase for high than for low baseline scores. This did not substantially change the results (data not shown). Second, although our sample size of IV-rtPA-treated patients with AIS was large, the actual number of END unexplained cases was relatively small, which limits the interpretation of the multivariate analyses. For instance, to reduce the risk of overfitting, age was removed as predictor because it had lowest univariate P value, yet including it in a model with 4 variables did not change the findings (data not shown). Of note, the internal validation using bootstrap analysis strengthened the overall multivariate results. Nevertheless, mild associations between some baseline variables and END unexplained may also have been missed. Last, our findings do not apply to END after endovascular therapy, which was a cause of a priori exclusion for this study.
Additional multicenter studies involving larger samples are warranted to confirm our findings, which if confirmed could lead to novel approaches to prevent post-thrombolysis END in high-risk patients.
SUPPLEMENTAL MATERIAL Supplemental Methods
Clinical data
Demographics, cigarette smoking, diabetes mellitus, atrial fibrillation, current treatment, systolic and diastolic blood pressure (BP), glycemia at admission and onset-to-treatment time (OTT) were prospectively recorded. The following post-treatment variables were also prospectively collected: BP (monitored every 15mins for the first hour post-treatment then every hour for 24hrs) and capillary glycemia (recorded at 4, 8, 16 and 24hrs). Subcutaneous insulin was administered each 4hrs if glycemia was >10mmol/L. Maximum changes between admission BP or glycemia and their lowest measure during the first 24hrs were calculated. The stroke mechanism was determined according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. 164 (53) 45 (14) 56 (18) 91 (30) 99 (32) 86 (28) 173 (56) 15 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 156 ( 50 (16) 157 (51) 102 (33) 73.1±12.6
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Findings from the internal validation, using bootstrap analyses
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